Improvements in asthma care...

... will have to be made through better inhalers not new drugs, according to one of the UK's leading asthma asthma
Asthma is a common chronic inflammatory airway disease, characterized by variable and recurring symptoms, reversible airflow obstruction and bronchospasm.

European Respiratory Society, Meeting, 2005

Our focus is on developing aerosol aerosol
An aerosol is a colloid of fine solid particles or liquid droplets, in air or another gas.
therapies that fulfill an unmet or undermet patient need and provide a “leap” in value, not just and incremental step. Throughout all our projects, we ask ourselves:

  1. How can we improve compliance and quality of life?
  2. Can we improve disease control or prevent symptoms?
  3. How can we reduce patient exposure to medication while still achieving the desired efficiacy and safety profiles?
  4. How can we minimize unwanted side effects? How can we improve long term safety?

In working to reach these goals, we work together with pharmaceutical partners interested in developing treatments aimed at answering the questions above.

In our Partner Pipeline, we work together with pharmaceutical partners interested in developing treatments aimed at answering the questions above. We enter into a licensing agreement for both device and formulation technology and both companies develop therapies as a comprehensive project.